Drug Delivery Technologies Market Forecast 2016-2026
Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes
What can be expected from the Drug Delivery Technologies Market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
Our 214-page report provides 137 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national drug delivery technologies market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.
See revenue forecasts for the leading regional and national markets How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including: • US • EU5 (Germany, France, UK, Spain and Italy) • Japan • China • India • Brazil • Russia • South Korea • Mexico • Rest of the World
Leading companies and potential for market growth Visiongain forecasts overall revenue for the Drug Delivery Technologies Market will reach $259.1bn in 2020. We predict high revenue growth over the forecast period driven by big pharma seeking diversification of their top-selling products and a growing demand for more patient-friendly treatments in healthcare.
Our work analyses the key companies in the market. See Visiongain’s analysis of ten leading companies, including: • Alkermes • 3M • Skyepharma • Becton Dickinson and Company (BD) • Antares Pharma • pSivida • Applied Pharma Research (APR) • Ethypharm • Glycologic • NanoPass Technologies
A company profile gives you the following information where available: • Discussion of a company’s activities and outlook including regional and national revenue shares • Historic revenue, analysis and discussion of company performance • Analysis of major products/services currently available on the market • Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the drug delivery technologies industry? Our new report discusses issues and events affecting the drug delivery technologies market. You will find discussions, including qualitative analyses: • Highly fragmented and competitive market with significant variations in different geographic regions • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities • Future opportunities for drug delivery technologies
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes report helps you: In summary, our 214-page report gives you the following knowledge: • Revenue forecasts to 2026 for the Drug Delivery Technologies market – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2026 for three major regional markets – US, EU5 and Rest of the World • Revenue forecasts to 2026 for the leading national markets – US, Germany, France, UK, Spain, Italy, Japan, China, India, Brazil, Russia, South Korea, Mexico and Rest of the World • Assessment of leading companies – analysis of services, business operations, revenue (where available) and mergers & acquisitions • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the drug delivery technologies market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Drug Delivery Technology Market Overview 1.2 Global Drug Delivery Technologies Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who Is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Drug Delivery Technology: An Introduction 2.1 Drug Delivery Technologies: Strategies to Improve Existing Drugs 2.2 The Global Drug Delivery Technology Market: Methods of Administration 2.2.1 The Biopharmaceutics Classification System and Using Better Tools to Model Drug Absorption 2.2.2 Sustained/Controlled Release Systems 2.2.3 Oral Drug Delivery: Swallowing Drugs to Reach a Target 2.2.4 Pulmonary Delivery: Delivered by Inhalation 2.2.5 Injection as a Route of Drug Delivery 2.2.6 Transdermal Delivery: More Patient-Friendly 2.2.7 Various Transmucosal Delivery Routes for Delivery 2.2.8 Ocular Delivery: Overcoming Unique Barriers 2.3 Regulation in the US 2.3.1 Regulation of Combination Products 2.3.2 FDA Guidelines for Injectors 2.4 Biopharmaceuticals 2.4.1 An Introduction to the Biological Drugs Market 2.4.2 Biologics: A Rising Drugs Market 2.4.3 Biologics with Associated Drug Delivery Technologies 2.4.4 Pegylated Interferons 2.4.5 Stiff Competition in Insulin Market Stimulating Investment in Drug Delivery Technologies 2.4.6 The Main Challenges Facing Biological Drug Delivery 2.5 Market Definition
3. Drug Delivery Technologies: Global Market, 2016-2026 3.1 The Global Drug Delivery Technology Market in 2015 3.2 The Global Drug Delivery Technology Market Forecast 2016-2026 3.3 Drug Delivery Technology: Drivers and Restraints 2016-2026 3.4 Biologics: A Driver for Growth in Drug Delivery Technologies 3.4.1 The Global Biological Drugs Market Forecast 3.4.2 Leading Classes of Biological Drugs 3.4.3 Monoclonal Antibodies: Largest Sector in Biologics 3.4.4 Human insulin: Leading the Therapeutic Protein Segment 3.4.5 Interferon Products for the Treatment of Hepatitis 3.5 Vaccines: Meeting the Unmet Needs 3.5.1 The Global Vaccines Market Forecast
4. Drug Delivery Technologies: Submarkets 2016-2026 4.1 The Global Drug Delivery Technology Market by Submarkets 4.2 How Will Segmental Market Shares Change to 2026? 4.3 Oral Drug Delivery Technology 4.3.1 Oral Drug Delivery Technology Market Forecast 2016-2026 4.3.2 Trends and Developments 4.3.2.1 Delivering APIs to the Colon 4.3.2.2 Google Investing in Robotic Pill 4.3.3 Oral Drug Delivery Technologies: Drivers and Restraints 2016-2026 4.4 Inhalable Drug Delivery Technology 4.4.1 Inhalable Drug Delivery Technology Market Forecast 2016-2026 4.4.2 Trends and Developments 4.4.2.1 Inhalable Liposomal Antibiotics to Penetrate Biofilms 4.4.2.2 Condensation Aerosol Generated by Heat 4.4.2.3 Is Inhaled Insulin Marketable? 4.4.3 Inhalable Drug Delivery Technologies: Drivers and Restraints 2016-2026 4.5 Injectable/Implantable Delivery Technology 4.5.1 Injectable/Implantable Delivery Technology Market Forecast 2016-2026 4.5.2 Trends and Developments 4.5.2.1 Ultrasound Activated Targeted Drug Delivery 4.5.2.2 Intradermal Vaccine Delivery 4.5.2.3 First Flu Vaccine Jet Injector Approved in the US 4.5.3 Injectable/Implantable Delivery Technologies: Drivers and Restraints 2016-2026 4.6 Transdermal Drug Delivery Technology 4.6.1 Transdermal Drug Delivery Technology Market Forecast 2016-2026 4.6.2 Trends and Developments 4.6.2.1 Iontophoretic Transdermal Patch for Migraine Approved in the US 4.6.2.2 Microneedle Patch for Vaccine Delivery 4.6.2.3 Ultrasonic Waveforms to Enlarge Skin Pores 4.7 Ocular Drug Delivery Technology 4.7.1 Ocular Drug Delivery Technology Market Forecast 2016-2026 4.7.2 Trends and Developments 4.7.2.1 Non-Surgical Microinjection to Retina and Choroid to be used for Gene Therapy 4.8 Nasal/Buccal Drug Delivery Technology 4.8.1 Nasal/Buccal Drug Delivery Technology Market Forecast 2015-2026 4.8.2 Trends and Developments 4.8.2.1 Nasal Spray with Live Attenuated Influenza Vaccine 4.8.2.2 Mucosal Vaccine Delivered through the Nose or Mouth 4.8.2.3 Buccal Insulin Spray in Clinical Trials
5. Drug Delivery Technologies: Leading National Markets, 2016-2026 5.1 Global Drug Delivery Technology Market: Regional Forecast 2016-2026 5.1.1 How Will Regional Market Shares Change to 2026? 5.2 US Drug Delivery Technology Market 2016-2026 5.2.1 US Drug Delivery Technology Market Forecast 2016-2026 5.2.2 Eli Lilly to Establish Drug Delivery Centre 5.3 EU5 Drug Delivery Technology Market 2016-2026 5.3.1 EU5 Drug Delivery Technology Market Forecast 2016-2026 5.3.2 EU5 Drug Delivery Technologies Market: CAGR (%) by Country, 2016-2026 5.3.3 EU5 Markets: Changing Market Shares by Country, 2016-2026 5.3.4 The German Drug Delivery Technology Market Forecast 2016-2026 5.3.5 The French Drug Delivery Technology Market Forecast 2016-2026 5.3.6 The UK Drug Delivery Technology Market Forecast 2016-2026 5.3.7 The Spanish Drug Delivery Technology Market Forecast 2016-2026 5.3.8 The Italian Drug Delivery Technology Market Forecast 2016-2026 5.4 Japanese Drug Delivery Technology Market 2016-2026 5.4.1 Japanese Drug Delivery Technology Market Forecast 2016-2026 5.4.2 The New Sakigake Designation System May Accelerate Innovative Drug Development 5.5 Chinese Drug Delivery Technology Market 2016-2026 5.5.1 Chinese Drug Delivery Technology Market Forecast 2016-2026 5.6 Indian Drug Delivery Technology Market 2016-2026 5.6.1 Indian Drug Delivery Technology Market Forecast 2016-2026 5.7 Brazilian Drug Delivery Technology Market 2016-2026 5.7.1 Brazilian Drug Delivery Technology Market Forecast 2016-2026 5.8 Russian Drug Delivery Technology Market 2016-2026 5.8.1 Russian Drug Delivery Technology Market Forecast 2016-2026 5.9 South Korean Drug Delivery Technology Market 2016-2026 5.9.1 South Korean Drug Delivery Technology Market Forecast 2016-2026 5.10 Mexican Drug Delivery Technology Market 2016-2026 5.10.1 Mexican Drug Delivery Technology Market Forecast 2016-2026 5.11 Rest of the World Drug Delivery Technology Market Forecast 2016-2026
6. Leading Companies in the Drug Delivery Technology Market, 2016-2026 6.1 Alkermes: Focused on Extended and Controlled Release 6.1.1 Alkermes: Drug Delivery Technology Portfolio 6.1.2 Long-Acting Injectables 6.1.3 Aristada vs. Abilify Maintena 6.1.4 Oral Controlled Release 6.1.4.1 Nanoparticle Technologies 6.1.5 Other Technologies 6.1.6 Alkermes: Product Portfolio 6.1.7 Alkermes: Pipeline Products 2016 6.1.8 Alkermes Recent Developments 6.1.8.1 Merger with Elan Drug Technologies 6.1.8.2 Alkermes: Future Outlook 6.1.9 Manufacturing Facility in Georgia Sold to Recro Pharma 6.2 3M: 50 Years of Drug Delivery Technology Development 6.2.1 3M: Drug Delivery Technology Portfolio 6.2.1.1 Oral and Topical Drug Delivery 6.2.1.2 MDI for Nasal and Inhalable Drugs 6.2.1.3 Transdermal patch Technology 6.2.1.4 Microneedle Technology 6.2.2 3M: Market Outlook 6.3 Skyepharma: Solutions for Inhalable, Oral, Topical and Injectable Drugs 6.3.1 Skyepharma: Drug Delivery Technology Portfolio 6.3.1.1 Inhalation Drug Delivery Technology 6.3.1.2 Oral Drug Delivery Technology 6.3.1.3 Injectable Drug Delivery Technology 6.3.1.4 Topical Drug Delivery Technology 6.3.2 Skyepharma: Pipeline Products 2016 6.3.3 Skyepharma: Market Outlook 6.4 Becton Dickinson and Company (BD): A History of Hypodermic Needles and Syringes 6.4.1 BD: Drug Delivery Technology Portfolio 6.4.1.1 Prefillable Syringe Systems 6.4.1.2 Self-Injection Systems 6.4.1.3 Pen Needles 6.4.1.4 Safety & Shielding Systems 6.4.2 BD: Future Outlook 6.4.3 New Infusion Set with BD FlowSmart Technology Cleared by FDA 6.4.4 BD Acquired Injection Safety Firms 6.5 Antares Pharma: Leading the Needle-Free Injector Market 6.5.1 Antares Pharma: Drug Delivery Product Portfolio 6.5.2 Antares Pharma: Future Outlook 6.5.3 Antares Pharma: Products in Development 6.6 pSivida: Targeting the Back of the Eye 6.6.1 pSivida: Drug Delivery Technology Portfolio 6.6.1.1 Durasert Technology 6.6.1.2 Tethadur Technology 6.6.2 pSivida: Pipeline Products 2016 6.6.3 pSidiva: Collaborations 6.6.4 pSivida: Future Outlook 6.7 Applied Pharma Research (APR) 6.7.1 APR’s Technology and Product Offerings 6.8 Ethypharm 6.8.1 Ethypharm’s Currently Marketed Products 6.9 Glycologic 6.9.1 Glycologic’s Drug Delivery Technologies 6.9.2 Glycologic’s Pipeline Developments 6.10 NanoPass Technologies 6.10.1 NanoPass Drug Delivery Products 6.10.1.1 Anti-aging Microdermabrasion 6.10.1.2 MicronJet Needle
7. Qualitative Analysis of the Drug Delivery Technology Market, 2016-2026 7.1 SWOT Analysis of the Drug Delivery Technology Market 7.2 Strengths 7.2.1 Increasing Competition and Patent Expiry in the Biologics Market 7.2.2 The Rise of Biosimilars 7.2.3 Increasing Global Diabetic Population 7.3 Weaknesses 7.3.1 Risk-Conscious Regulatory Bodies Will Make Approval Difficult 7.3.2 Companies Need to Develop a More Liberal Mindset 7.4 Opportunities 7.4.1 Nanotechnology: Innovations That Will Benefit Drug Delivery 7.4.2 Possible New Delivery Methods for Insulin 7.5 Threats 7.5.1 Increasing Specificity of Drug Development Poses Challenges to Speciality Drug Delivery Companies 7.5.2 Cost Effective Solutions May Not Be Available
8. Expert Opinions from Our Primary Research 8.1 Mr. Patrice Lewko, Vice President — Global Marketing & Innovation, Nemera 8.1.1 The Current state of the Drug Delivery Technologies Market 8.1.2 Key Pointers to Entering the Drug Delivery Technologies Market 8.1.3 The Key to Success for Novelia 8.1.4 Regions of Interest for Nemera and Prospects for Future Growth 8.1.5 Prospects for New Technologies 8.1.6 Major Challenges and Opportunities 8.2 Mr. Armand Amin, Manager — Systems Development, BioDuro 8.2.1 BioDuro Drug Delivery Technology Solutions 8.2.2 The Importance of Timing 8.2.3 The Current State of the Drug Delivery Technologies Market 8.2.4 Entering the Drug Delivery Technologies Market 8.2.5 New Technologies to Enter the Market 8.2.6 Future Challenges and Opportunities for Drug Delivery Technologies 8.2.7 Opportunities for Growth
9. Conclusions 9.1 The Global Drug Delivery Technologies Market in 2015 9.1.1 Current Leading Drug Delivery Technology Segments 9.1.2 Notable Drug Delivery Technology Companies 9.1.3 Leading Regional/National Markets 9.2 Global Drug Delivery Technology Market Forecast 2016-2026 9.3 The Future of the Drug Delivery Technology Market 9.3.1 Transdermal and Injectable Drug Delivery Technologies Set For High Growth 9.3.2 Biologics and Biosimilars to Drive Market Growth
10. Glossary
Appendix Visiongain’s Bespoke Research Service Some Associated Reports Visiongain Report Sales Order Form About Visiongain Report Evaluation Form
List of Tables Table 1.1 Global Drug Delivery Technologies Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2015-2026 (Redacted Data) Table 2.1 The Biopharmaceutics Classification System, Classification and Description Table 2.2 Top 5 Biologics by Sales ($bn), 2015 Table 3.1 The Global Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 3.2 Global Biological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 3.3 Global Vaccines Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.1 The Global Drug Delivery Technology Market by Submarkets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.2 Leading Drug Delivery Market Segments: CAGR (%), 2015-2020, 2020-2026 and 2015-2026 Table 4.3 Leading Drug Delivery Market Segments: Market Share (%), 2015 Table 4.4 Oral Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.5 Inhalable Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.6 Insulin Inhalers Withdrawal from the Market or Pipeline, 2016 Table 4.7 Injectable/Implantable Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.8 Transdermal Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.9 Ocular Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.10 Nasal/Buccal Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.1 The Global Drug Delivery Technologies Market by Country/Region: Revenue ($bn) and Market Share (%), 2015 Table 5.2 Global Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Country/Region, 2015-2026 Table 5.3 Global Drug Delivery Technology Market: Revenue ($bn) by Country/Region, 2015, 2020 and 2026 Table 5.4 Global Drug Delivery Technology Market: Revenue ($bn) and Market Share (%) by Country/Region, 2015 Table 5.5 US Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.6 EU5 Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.7 EU5 Drug Delivery Technology Market: CAGR (%) by Country, 2015-2020, 2020-2026 and 2015-2026 Table 5.8 EU5 Drug Delivery Technology Market: Market Size ($bn) and Market Share (%) by Country, 2015, 2020 and 2026 Table 5.9 German Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.10 French Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.11 UK Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.12 Spanish Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.13 Italian Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.14 Japanese Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.15 Chinese Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.16 Indian Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.17 Brazilian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Table 5.18 Russian Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.19 South Korean Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.20 Mexican Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.21 Rest of the World Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.1 Leading Companies: Areas of Interest by Type of Delivery Table 6.2 Alkermes: Overview, 2016 Table 6.3 Alkermes: Drug Delivery Technology Portfolio and Pipeline 2016 Table 6.4 Products Utilising Alkermes’ Drug Delivery Technology (Indication, Partner and Territory) 2016 Table 6.5 Alkermes: Pipeline Products (Product Candidate, Target Indication and Status), 2016 Table 6.6 Alkermes: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 6.7 Alkermes: Historical Revenue ($m) by Business Segment, 2010-2015 Table 6.8 Alkermes: Manufacturing and Royalty Revenue ($m) by Product, 2014 and 2015 Table 6.9 Alkermes: Revenue ($m) by Main Customers 2014 Table 6.10 3M: Overview, 2016 Table 6.11 3M: Health Care Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2015 Table 6.12 Skyepharma: Overview, 2015 Table 6.13 Skyepharma: Inhalation Drug Formulation Technology Portfolio 2016 Table 6.14 Products Utilising Skyepharma’s Inhalation Drug Delivery Technology (Product Name, Indication, Licensee and Description), 2015 Table 6.15 Skyepharma: Oral Drug Formulation Technology Portfolio (Technology, Description and Product Name) 2016 Table 6.16 Products Utilising Skyepharma’s Oral Drug Delivery Technology (Product Name, Indication, Licensee and Description), 2016 Table 6.17 Skyepharma: Pipeline Products 2016 (Product Name, Formulation, Region, Indication, Partner Name and Status) Table 6.18 Skyepharma: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 6.19 Skyepharma: Historical Revenue ($m) by Income Stream, 2010-2015 Table 6.20 BD: Overview, 2016 Table 6.21 BD: Drug Delivery Products by Segment, 2016 Table 6.22 BD: Historical Revenue ($bn) by Geographic Region, 2012-2015 Table 6.23 BD Medical: Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2015 Table 6.24 Antares Pharma: Overview, 2016 Table 6.25 Antares Pharma: Product Portfolio (Product, Drug, Partner, Indication and Territory Table 6.26 Antares Revenue from Major Customers: Revenue ($m) and Revenue Share (%), 2014 and 2015 Table 6.27 Antares Revenue by Region: Revenue ($m) and Revenue Share (%), 2014 and 2015 Table 6.28 Antares Pharma: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 6.29 Antares Pharma: Products in Development 2016 (Product Name, Drug, Partner, Indication, Territory and Regulatory Status) Table 6.30 pSivida: Overview, 2015 Table 6.31 Products Utilising Durasert Technology 2015 (Product, Indication, Status and Partner) Table 6.32 pSivida: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015 Table 6.33 pSivida: Historical Revenue ($m) by Income Stream, 2010-2015 Table 6.34 Selected Ethypharm’s Pain Relieving Products, 2015 Table 7.1 SWOT Analysis of the Drug Delivery Technology Market, 2016-2026
List of Figures Figure 3.1 The Global Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 3.2 Drug Delivery Technologies: Market Drivers and Restraints 2016-2026 Figure 3.3 Global Biological Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 3.4 Global Vaccines Market: Revenues ($bn) and AGR (%), 2015-2026 Figure 4.1 Leading Drug Delivery Market Segments: CAGR (%), 2015-2020 Figure 4.2 Leading Drug Delivery Market Segments: CAGR (%), 2020-2026 Figure 4.3 Leading Drug Delivery Market Segments: CAGR (%), 2015-2026 Figure 4.4 Market Shares (%) of Leading Drug Delivery Market Segments, 2015 Figure 4.5 Market Shares (%) of Leading Drug Delivery Market Segments, 2020 Figure 4.6 Market Shares (%) of Leading Drug Delivery Market Segments, 2026 Figure 4.7 Oral Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.8 Oral Drug Delivery Technologies: Drivers and Restraints 2016-2026 Figure 4.9 Inhalable Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.10 Inhalable Drug Delivery Technologies: Drivers and Restraints 2016-2026 Figure 4.11 Injectable/Implantable Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.12 Injectable/implantable Drug Delivery Technologies: Drivers and Restraints 2015-2026 Figure 4.13 Transdermal Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.14 Ocular Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.15 Nasal/Buccal Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.1 The Global Drug Delivery Technologies Market by Country/Region: Revenue ($bn), 2015 Figure 5.2 Global Drug Delivery Technology Market: Revenue ($bn) by Country/Region, 2015, 2020 and 2026 Figure 5.3 Global Drug Delivery Technology Market: CAGR (%) by Country/Region, 2015-2020 Figure 5.4 Global Drug Delivery Technology Market: CAGR (%) by Country/Region, 2020-2026 Figure 5.5 Global Drug Delivery Technology Market: CAGR (%) by Country/Region 2015-2026 Figure 5.6 Global Drug Delivery Technology Market: Market Share (%) by Country/Region, 2015 Figure 5.7 Global Drug Delivery Technology Market: Market Share (%) by Country/Region, 2020 Figure 5.8 Global Drug Delivery Technology Market: Market Share (%) by Country/Region, 2026 Figure 5.9 US Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.10 EU5 Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.11 EU5 Drug Delivery Technology Market: CAGR (%) by Country, 2015-2020 Figure 5.12 EU5 Drug Delivery Technology Market: by Country, 2020-2026 Figure 5.13 EU5 Drug Delivery Technology Market: CAGR (%) by Country, 2015-2026 Figure 5.14 EU5 Drug Delivery Technology Market: Market Share (%) by Country, 2015 Figure 5.15 EU5 Drug Delivery Technology Market: Market Share (%) by Country, 2020 Figure 5.16 EU5 Drug Delivery Technology Market: Market Share (%) by Country, 2026 Figure 5.17 German Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.18 French Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.19 UK Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.20 Spanish Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.21 Italian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.22 Japanese Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.23 Chinese Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.24 Indian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.25 Brazilian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.26 Russian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.27 South Korean Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.28 Mexican Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.29 Rest of the World Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.1 Alkermes: Historical Revenue ($m) and AGR (%), 2010-2015 Figure 6.2 Alkermes Historical Revenue ($m): Manufacturing and Royalty Turnover, and Net Product Sales, 2010-2015 Figure 6.3 Alkermes: Manufacturing and Royalty Revenue ($m) by Product, 2014 and 2015 Figure 6.4 Alkermes: Revenue Share (%) by Main Customers 2014 Figure 6.5 Alkermes: Revenue Share (%) by Main Customers 2015 Figure 6.6 3M: Health Care Historical Revenue ($bn) and AGR (%), 2010-2015 Figure 6.7 Skyepharma: Historical Revenue ($m) and AGR (%), 2010-2015 Figure 6.8 Skyepharma: Historical Revenue ($m) by Income Stream, 2010-2015 Figure 6.9 BD: Historical Revenue ($bn) by Geographic Region, 2012-2015 Figure 6.10 BD Medical: Historical Revenue ($bn) and AGR (%), 2010-2015 Figure 6.11 Antares Revenue from Major Customers: Revenue Share (%), 2014 Figure 6.12 Antares Revenue from Major Customers: Revenue Share (%), 2015 Figure 6.13 Antares Revenue by Region: Revenue Share (%), 2014 Figure 6.14 Antares Revenue by Region: Revenue Share (%), 2015 Figure 6.15 Antares Pharma: Historical Revenue ($m) and AGR (%), 2010-2015 Figure 6.16 pSivida: Historical Revenue ($m) and AGR (%), 2010-2015 Figure 6.17 pSivida: Historical Revenue ($m) by Income Stream, 2010-2015
3M Acorda Actavis Adamis Aleza Pharmaceuticals Alkermes Almirall Alza Antares Pharma Applied Pharma Research Aradigm Astellas AstraZeneca Bayer HealthCare Pharmaceuticals BD Biogen BioGeneration Ventures Bioject Medical Technologies Boehringer Ingelheim Bristol¬Myers Squibb CareFusion Corporation Cephalon Changchun BCHT Chiesi Chrono Therapeutics Cilag Cima Labs Clearside Cosmo Pharmaceuticals CRISI Medical Systems CTCBIO Daiichi Elan Drug Technologies Elcam Medical Eli Lilly Ethypharm Ferrer Ferring Flamel Genentech GlaxoSmithKline Glycologic Google GSK Haselmeir Horizon Pharma ImmusanT Innovent Biologics Insmed Invion iScience Interventional Corporation J&J Janssen JCR Pharmaceuticals Kyorin MannKind Meda Pharmaceuticals Medac Medimetrics MedImmune MedSciences Capital Merck Serono Mucosis Mundipharma Nanopass Technologies Nektar Therapeutics Nexvax2 NHTherapeutics Novartis Novo Nordisk NuPathe NV NOM Oramed OwenMumford Pacira Pharmaceuticals Pari Pharma Permatec Pfizer PharmaJet Presspart ProStrakan pSivida Pulmagen Ranbaxy Rani Therapeutics Recro Pharma Regeneron Pharmaceuticals Roche Sandoz Sanofi-Aventis Santen Shionogi SHL Group Shreya Life Sciences Skyepharma Smoofi Spark Therapeutics STADA Arzneimittel Takeda Teva UU Holdings Vetter Pharma West Pharmaceuticals Ypsomed
Organisations Mentioned in the Report Emory University School of Medicine Georgia Institute of Technology Hospital for Special Surgery University of Oxford
Download sample pages
Complete the form below to download your free sample pages for Drug Delivery Technologies Market Forecast 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Drug Delivery Technologies Market Forecast 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Despite a number of obstacles, the global anti-obesity drugs market is projected to grow at a significant growth over the next decade. This is mostly due to certain new trends that have the ability to positively impact the industry.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
